ONCT

Oncternal Therapeutics, Inc.

8.90 USD
+0.85 (+10.56%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Oncternal Therapeutics, Inc. stock is up 3.25% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 20 June’s closed higher than May. 100% of analysts rate it a buy.

About Oncternal Therapeutics, Inc.

Oncternal Therapeutics, Inc. focuses on the development of oncology therapies for cancers with critical unmet medical needs. Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1)